Virtually screened novel sulfathiazole derivatives as a potential drug candidate for methicillin-resistant Staphylococcus aureus and multidrug-resistant tuberculosis

References

• Alexander, P. E., & De, P. (2007). The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses et de la Microbiologie Medicale, 18(5), 289–291. https://doi.org/10.1155/2007/986794
   PubMed Web of Science ®Google Scholar
• Balasubramaniyan, S., Irfan, N., Umamaheswari, A., & Puratchikody, A. (2018). Design and virtual screening of novel fluoroquinolone analogs as effective mutant DNA GyrA inhibitors against urinary tract infection-causing fluoroquinolone resistant Escherichia coli. RSC Advances, 8(42), 23629–23647. https://doi.org/10.1039/c8ra01854e
   PubMed Web of Science ®Google Scholar
• Chen, J., Wang, J., Pang, L., Wang, W., Zhao, J., & Zhu, W. (2021). Deciphering molecular mechanism behind conformational change of the São Paolo metallo-β-lactamase 1 by using enhanced sampling. Journal of Biomolecular Structure and Dynamics, 39(1), 140–151. https://doi.org/10.1080/07391102.2019.1707121
   PubMed Web of Science ®Google Scholar
• Chen, J., Wang, X., Pang, L., Zhang, J. Z., & Zhu, T. (2019). Effect of mutations on binding of ligands to guanine riboswitch probed by free energy perturbation and molecular dynamics simulations. Nucleic Acids Research, 47(13), 6618–6631.
   PubMed Web of Science ®Google Scholar
• Chinthakindi, P. K., Naicker, T., Thota, N., Govender, T., Kruger, H. G., & Arvidsson, P. I. (2017). Sulfonimidamides in medicinal and agricultural chemistry. Angewandte Chemie (International ed. in English), 56(15), 4100–4109. https://doi.org/10.1002/anie.201610456
   PubMed Web of Science ®Google Scholar
• Cole, S.T., & Riccardi, G., New tuberculosis drugs on the horizon, Current Opinion in Pulmonary Medicine, 14 (2011) 570–576.
   Google Scholar
• de Sa, A., Fernando, R., Barreiro, J. E., Fraga, M., & Carlos, A. (2009). From nature to drug discovery: The indole scaffold as a 'privileged structure'. Mini Reviews in Medicinal Chemistry, 9(7), 782–793. https://doi.org/10.2174/138955709788452649
   PubMed Web of Science ®Google Scholar
• Elsebaei, M. M., Mohammad, H., Abouf, M., Abutaleb, N. S., Hegazy, Y. A., Ghiaty, A., Chen, L., Zhang, J., Malwal, S. R., Oldfield, E., Seleem, M. N., & Mayhoub, A. S. (2018). Alkynyl-containing phenylthiazoles: systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA)). European Journal of Medicinal Chemistry, 148, 195–209. https://doi.org/10.1016/j.ejmech.2018.02.031
   PubMed Web of Science ®Google Scholar
• Enright, M. C., Robinson, D. A., Randle, G., Feil, E. J., Grundmann, H., & Spratt, B. G. (2002). May 28 The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proceedings of the National Academy of Sciences of the United States of America, 99(11), 7687–7692. https://doi.org/10.1073/pnas.122108599
   PubMed Web of Science ®Google Scholar
• Frazee, B. W., Lynn, J., Charlebois, E. D., Lambert, L., Lowery, D., & Perdreau-Remington, F. (2005). High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Annals of Emergency Medicine, 45(3), 311–320. https://doi.org/10.1016/j.annemergmed.2004.10.011
   PubMed Web of Science ®Google Scholar
• Fridkin, S. K., Hageman, J. C., Morrison, M., Sanza, L. T., Como-Sabetti, K., Jernigan, J. A., Harriman, K., Harrison, L. H., Lynfield, R., & Farley, M. M, Active Bacterial Core Surveillance Program of the Emerging Infections Program Network (2005). Methicillin-resistant Staphylococcus aureus disease in three communities. The New England Journal of Medicine, 352(14), 1436–1444. https://doi.org/10.1056/NEJMoa043252
   PubMed Web of Science ®Google Scholar
• Global tuberculosis Report 2019 (2019). Retrieved October 17, 2019, from https://www.who.int/tb/publications/global_report/en/.
   Google Scholar
• Grosset, J. H., Singer, T. G., & Bishai, W. R. (2012). New drugs for the treatment of tuberculosis: Hope and reality. The International Journal of Tuberculosis and Lung Disease, 16(8), 1005–1014. https://doi.org/10.5588/ijtld.12.0277
   PubMed Web of Science ®Google Scholar
• Han, L. L., McDougal, L. K., Gorwitz, R. J., Mayer, K. H., Patel, J. B., Sennott, J. M., & Fontana, J. L. (2007). High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. Journal of Clinical Microbiology, 45(4), 1350–1352. https://doi.org/10.1128/JCM.02274-06
   PubMed Web of Science ®Google Scholar
• Hassoun, A., Linden, P. K., & Friedman, B. (2017). Incidence, prevalence, and management of MRSA bacteremia across patient populations—a review of recent developments in MRSA management and treatment. Critical Care (London, England), 21(1), 211.
   PubMedGoogle Scholar
• Havlir, D. V., Getahun, H., Sanne, I., & Nunn, P, WHO (2010). Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA, 200(300), 423–430.
   Google Scholar
• Henry, F., & Chambers, M. D. (2005). Community-associated MRSA-resistance and virulence converge. The New England Journal of Medicine, 352(14), 1485–1487. https://doi.org/10.1056/NEJMe058023
   PubMed Web of Science ®Google Scholar
• Hiramatsu, K. (2001). Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance. The Lancet. Infectious Diseases, 1(3), 147–155. https://doi.org/10.1016/S1473-3099(01)00091-3
   PubMedGoogle Scholar
• Khan, A., Wilson, B., & Gould, I. M. (2018). Current and future treatment options for community-associated MRSA infection. Expert Opinion on Pharmacotherapy, 19(5), 457–470. https://doi.org/10.1080/14656566.2018.1442826
   PubMed Web of Science ®Google Scholar
• Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011). The challenge of new drug discovery for tuberculosis. Nature, 469(7331), 483–490. https://doi.org/10.1038/nature09657
   PubMed Web of Science ®Google Scholar
• Kourtis, A. P., Hatfield, K., Baggs, J., Mu, Y., See, I., Epson, E., Nadle, J., Kainer, M. A., Dumyati, G., Petit, S., Ray, S. M., Emerging Infections Program, M., Ham, D., Capers, C., Ewing, H., Coffin, N., McDonald, L. C., Jernigan, J., & Cardo, D, Emerging Infections Program MRSA author group (2019). Vital signs: Epidemiology and recent trends in methicillin resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections - United States. MMWR. Morbidity and Mortality Weekly Report, 68(9), 214–219. https://doi.org/10.15585/mmwr.mm6809e1
   PubMed Web of Science ®Google Scholar
• Lamichhane, G. (2011). Novel targets in M. tuberculosis: search for new drugs. Trends in Molecular Medicine, 17(1), 25–33. https://doi.org/10.1016/j.molmed.2010.10.004
   PubMed Web of Science ®Google Scholar
• Lee, A. S., de Lencastre, H., Garau, J., Kluytmans, J., Malhotra-Kumar, S., Peschel, A., & Harbarth, S. (2018). Methicillin-resistant Staphylococcus aureus. Nature Reviews. Disease Primers, 4, 18033. https://doi.org/10.1038/nrdp.2018.33
   PubMed Web of Science ®Google Scholar
• Lienhardt, C., Vernon, A., & Raviglione, M. C. (2010). New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine, 16, 186–193.
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23(1-3), 3–25. https://doi.org/10.1016/S0169-409X(96)00423-1
   Web of Science ®Google Scholar
• Locke, J. B., Morales, G., Hilgers, M., G C, K., Rahawi, S., José Picazo, J., Shaw, K. J., & Stein, J. L. (2010). Elevated linezolid resistance in clinical CFR-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3. Antimicrobial Agents and Chemotherapy, 54(12), 5352–5355. https://doi.org/10.1128/AAC.00714-10
   PubMed Web of Science ®Google Scholar
• Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., & Talan, D. A, EMERGEncy ID Net Study Group (2006). Methicillin-resistant S. aureus infections among patients in the emergency department. The New England Journal of Medicine, 355(7), 666–674. https://doi.org/10.1056/NEJMoa055356
   PubMed Web of Science ®Google Scholar
• Mun, S.-H., Kim, S.-B., Kong, R., Choi, J.-G., Kim, Y.-C., Shin, D.-W., Kang, O.-H., & Kwon, D.-Y. (2014). Curcumin reverse methicillin resistance in Staphylococcus aureus. Molecules (Basel, Switzerland), 19(11), 18283–18295. https://doi.org/10.3390/molecules191118283
   PubMed Web of Science ®Google Scholar
• Navabshan, I., Sakthivel, B., Pandiyan, R., Antoniraj, M. G., Dharmaraj, S., Ashokkumar, V., Khoo, K. S., Chew, K. W., Sugumaran, A., & Show, P. L. (2021). Correction to: Computational lock and key and dynamic trajectory analysis of natural biophors against COVID-19 spike protein to identify effective lead molecules. Molecular Biotechnology, 63(10), 898–908. https://doi.org/10.1007/s12033-021-00358-z
   PubMed Web of Science ®Google Scholar
• Patel, J. B., Gorwitz, R. J., & Jernigan, J. A. (2009). Mupirocin resistance. Clinical Infectious Diseases, 49(6), 935–941. https://doi.org/10.1086/605495
   PubMed Web of Science ®Google Scholar
• Puratchikody, A., Irfan, N., & Balasubramaniyan, S. (2019). Conceptual design of hybrid PCSK9 lead inhibitors against coronary artery disease. Biocatalysis and Agricultural Biotechnology, 17, 427–440. Jan 1https://doi.org/10.1016/j.bcab.2018.12.014
   Web of Science ®Google Scholar
• Rodvold, K. A., & McConeghy, K. W. (2014). Methicillin-resistant Staphylococcus aureus therapy: Past, present, and future. Clinical Infectious Diseases, 58(suppl 1), S20–S27. https://doi.org/10.1093/cid/cit614
   PubMed Web of Science ®Google Scholar
• Singh, A., Fatima, K., Srivastava, A., Khwaja, S., Priya, D., Singh, A., Mahajan, G., Alam, S., Saxena, A. K., Mondhe, D. M., Luqman, S., Chanda, D., Khan, F., & Negi, A. S. (2016). Anticancer activity of gallic acid template-based benzylidene indanone derivative as microtubule destabilizer. Chemical Biology & Drug Design, 88(5), 625–634. https://doi.org/10.1111/cbdd.12805
   PubMed Web of Science ®Google Scholar
• Tenover, F. C., Sinner, S. W., Segal, R. E., Huang, V., Alexandre, S. S., McGowan, J. E., & Weinstein, M. P. (2009). Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. International Journal of Antimicrobial Agents, 33(6), 564–568. https://doi.org/10.1016/j.ijantimicag.2008.12.010
   PubMed Web of Science ®Google Scholar
• Tuberculosis Drug Screening Program. (2001). Search for new drugs for treatment of tuberculosis. Antimicrobial Agents and Chemotherapy, 45, 1943–1946.
   PubMed Web of Science ®Google Scholar
• Van Boogaard Den, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., & Aarnoutse, R. E. (2009). New drugs against tuberculosis: Problems, progress, and evaluation of agents in clinical development. Antimicrobial Agents and Chemotherapy, 53(3), 849–862. https://doi.org/10.1128/AAC.00749-08
   PubMed Web of Science ®Google Scholar
• WHO. WHO Global Tuberculosis Report. WHO Report, (2014) 2013–2014.
   Google Scholar
• Wilson, P., Andrews, J. A., Charlesworth, R., Walesby, R., Singer, M., Farrell, D. J., & Robbins, M. (2003). Linezolid resistance in clinical isolates of Staphylococcus aureus. The Journal of Antimicrobial Chemotherapy, 51(1), 186–188. https://doi.org/10.1093/jac/dkg104
   PubMed Web of Science ®Google Scholar
• Winum, J.-Y., Maresca, A., Carta, F., Scozzafava, A., & Supuran, C. T. (2012). Polypharmacology of sulfonamides: Pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases. Chemical Communications (Cambridge, England), 48(66), 8177–8179. https://doi.org/10.1039/c2cc33415a
   PubMed Web of Science ®Google Scholar
• Yousuf, S. K., Taneja, S. C., & Mukherjee, D. (2010). Multicomponent cascade transformation of d-glucal to furan-appended triazole glycoconjugates. The Journal of Organic Chemistry, 75(9), 3097–3100. https://doi.org/10.1021/jo100475e
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Post-Martens, K., & Denkin, S. (2006). New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discovery Today, 11(1-2), 21–27. https://doi.org/10.1016/S1359-6446(05)03626-3
   PubMed Web of Science ®Google Scholar
• Zumla, A., Raviglione, M., Hafner, R., & Fordham von Reyn, C. (2013). Tuberculosis. The New England Journal of Medicine, 368(8), 745–755. https://doi.org/10.1056/NEJMra1200894
   PubMed Web of Science ®Google Scholar